CTXR - CIK 0001506251
The table below shows Citius Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.59M | $7.72M | $6.09M | $26.41K | $1.10M | $17.91M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $1.08M | $4.05M | - | - | - | - |
| Inventory | $22.66M | $22.64M | $17.21M | $15.34M | $14.38M | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $31.69M |
| $37.95M |
| $24.61M |
| $18.37M |
| $18.33M |
| $28.01M |
| Property, plant & equipment | - | - | - | - | - | $1.43K |
| Goodwill | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M | $9.35M |
| Total assets | $132.54M | $140.39M | $127.68M | $121.48M | $120.70M | $97.09M |
| Accounts payable | $9.45M | $11.02M | $10.09M | $9.37M | $7.36M | $1.66M |
| Total current liabilities | $55.02M | $38.21M | $51.84M | $49.88M | $44.81M | $4.15M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $63.46M | $46.92M | $60.12M | $57.91M | $51.78M | $10.81M |
| Retained earnings | -$268.26M | -$247.02M | -$230.84M | -$222.05M | -$211.14M | -$190.58M |
| Total equity | $61.54M | $79.96M | $65.06M | $60.66M | $65.41M | $85.68M |